MENLO PARK, Calif. — December 9, 2025 — Leads & Copy — BillionToOne, Inc. (NASDAQ: BLLN) has released its financial results for the third quarter ending September 30, 2025, and initiated guidance for the rest of the year. The next-generation molecular diagnostics company, aims to create accurate tests accessible to all.
Key financial highlights from the third quarter of 2025 include:
Total revenue reached $83.5 million, a 117% increase compared to $38.4 million in the third quarter of 2024.
Prenatal clinical testing revenue was $74.1 million, up 102% from $36.6 million in the same quarter the previous year.
Oncology clinical testing revenue increased to $8.7 million, a 7.6-fold rise from $1.1 million in the third quarter of 2024, and a 76% increase compared to $4.9 million in the second quarter of 2025.
Gross margin was 70%, compared to 53% in the third quarter of 2024, marking a 17 percentage-point increase year-over-year.
The company accessioned 162,900 tests, a 51% increase from 107,900 tests in the third quarter of 2024.
Operating income was $9.6 million, a notable improvement from the $12.6 million operating loss in the third quarter of 2024.
BillionToOne reported positive cash flow of $6.2 million.
The company raised gross proceeds of $314.0 million through its initial public offering (IPO).
The company anticipates full-year 2025 revenue between $293 million and $299 million, reflecting a 92% to 96% growth compared to 2024. For the fourth quarter of 2025, the company projects revenue to be in the range of $84 million to $90 million, representing an 86% to 100% increase over the fourth quarter of the previous year.
BillionToOne also expects positive operating income for both the fourth quarter and the entirety of 2025.
Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne, stated that the company’s financial performance demonstrates the impact of its technology and disciplined execution in molecular diagnostics. He added that the company is committed to solving unmet clinical needs and is focused on scientific rigor and resourcefulness. Dr. Atay noted that the company remains guided by its principles as it moves forward as a public entity.
The company held approximately $195.2 million in cash and cash equivalents as of September 30, 2025. Net proceeds from the IPO totaled approximately $286.4 million.
BillionToOne hosted a conference call on December 9, 2025, to discuss these results. A webcast of the call is available on the company’s investor relations website.
BillionToOne’s Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.
Contact:
ir@billiontoone.com
billiontoone@moxiegrouppr.com
Source: BillionToOne
